| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/26/2013 | US8383086 Nicotinamide riboside kinase compositions and methods for using the same |
| 02/26/2013 | CA2632013C Adenovirus 36 e4 orf 1 gene and protein and their uses |
| 02/26/2013 | CA2542035C Process for producing antithrombin iii composition |
| 02/26/2013 | CA2477312C Use of soluble fgl2 as an immunosuppressant |
| 02/26/2013 | CA2440775C The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 02/26/2013 | CA2389644C A novel polypeptide hormone phosphatonin |
| 02/26/2013 | CA2327586C Fap.alpha.-specific antibody with improved producibility |
| 02/26/2013 | CA2324648C Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| 02/26/2013 | CA2324381C An integrin heterodimer and a subunit thereof |
| 02/25/2013 | CA2750419A1 Novel treatment, prevention or diagnosis of health problems |
| 02/21/2013 | WO2013026021A2 Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
| 02/21/2013 | WO2013026015A1 Muc1 ligand traps for use in treating cancers |
| 02/21/2013 | WO2013025969A1 Treatments for gastrointestinal disorders |
| 02/21/2013 | WO2013025941A1 Low protein percentage gelling compositions |
| 02/21/2013 | WO2013025936A1 Detection and treatment of metastatic disease |
| 02/21/2013 | WO2013025861A1 Compounds and methods for augmenting permeability barriers |
| 02/21/2013 | WO2013025846A2 Transferrin-tumstatin fusion protein and methods for producing and using the same |
| 02/21/2013 | WO2013025538A2 Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
| 02/21/2013 | WO2013025474A2 Compositions and methods for regulating neutrophil movement and neutrophil numbers in a body region |
| 02/21/2013 | WO2013025064A2 Anti-cancer composition comprising wnt decoy receptors |
| 02/21/2013 | WO2013024582A1 Mphosph1 peptides and vaccines including the same |
| 02/21/2013 | WO2013024362A2 Cardiovascular therapeutics |
| 02/21/2013 | WO2013024243A1 Inhibitors against endosomal/lysosomal enzymes |
| 02/21/2013 | WO2013024158A1 Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
| 02/21/2013 | WO2013024074A1 Plasminogen and plasmin variants |
| 02/21/2013 | WO2013024040A2 Tnf superfamily trimerization inhibitors |
| 02/21/2013 | WO2013023961A1 Use of interferon beta for the treatment of alopecia areata |
| 02/21/2013 | WO2013023443A1 Pharmaceutical application of peptide of soft-shell turtle |
| 02/21/2013 | WO2013023442A1 Pharmaceutical application of peptide of soft-shell turtle |
| 02/21/2013 | WO2013023319A1 In vitro method for modifying the depletion profile of treg cells present in a total splenocyte population of a biological sample by means of the isolation, culturing and exposure thereof to an atp and polymixin b medium |
| 02/21/2013 | WO2013006451A3 Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof |
| 02/21/2013 | WO2013003449A3 Methods of treatment with glp-1 receptor agonists |
| 02/21/2013 | WO2013002485A3 Pharmaceutical composition for preventing and treating kidney disorders, containing inhibitor for phosphorylation of taz tyrosine as active ingredient for activation of nfat5/tonebp |
| 02/21/2013 | WO2012177929A3 Methods for treating diabetes with extended release formulations of glp-1 receptor agonists |
| 02/21/2013 | WO2012177660A3 Leukotoxin e/d as a new anti-inflammatory agent and microbicide |
| 02/21/2013 | WO2012174489A3 Small molecule composite surfaces as inhibitors of protein-protein interactions |
| 02/21/2013 | WO2012174028A3 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
| 02/21/2013 | WO2012172427A3 Peptide compounds for inhibition of platelet aggregation |
| 02/21/2013 | WO2012162394A3 Compositions and methods for treating renal disease |
| 02/21/2013 | WO2012158624A3 Inhibitors of mitochondrial fission and methods of use thereof |
| 02/21/2013 | WO2012156296A8 Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients |
| 02/21/2013 | WO2012112792A3 Multicomponent compositions and their uses |
| 02/21/2013 | WO2012009576A9 Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid |
| 02/21/2013 | US20130046283 Methods and intravascular treatment devices for treatment of atherosclerosis |
| 02/21/2013 | US20130046257 Methods of using agents that modulate claudin expression |
| 02/21/2013 | US20130046077 Dolastatin 15 derivatives |
| 02/21/2013 | US20130045929 Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan |
| 02/21/2013 | US20130045928 Uses of Natriuretic Peptide Constructs |
| 02/21/2013 | US20130045927 Therapeutic compositions for the treatment of dry eye disease |
| 02/21/2013 | US20130045926 Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema |
| 02/21/2013 | US20130045925 Compositions for ameliorating cell proliferative disorders and methods of making and using them |
| 02/21/2013 | US20130045924 Methods of reducing hypoxic stress in a mammal by administering soluble p-selectin |
| 02/21/2013 | US20130045923 Collagenous material |
| 02/21/2013 | US20130045922 Pro-angiogenic fragments of prominin-1 and uses thereof |
| 02/21/2013 | US20130045921 Therapeutic agent for rhinitis |
| 02/21/2013 | US20130045920 Flowable Ceramic Putty |
| 02/21/2013 | US20130045919 Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents |
| 02/21/2013 | US20130045918 Methods for Treating Diabetic Wounds |
| 02/21/2013 | US20130045917 Method of selecting polypeptide sequence, and metal oxide or silicon-containing compound binding peptide and use thereof |
| 02/21/2013 | US20130045916 Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof |
| 02/21/2013 | US20130045915 Method for weight loss and ketogenic compositions |
| 02/21/2013 | US20130045914 Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| 02/21/2013 | US20130045278 Skin formulation, preparation and uses thereof |
| 02/21/2013 | US20130045277 Biocompatible device |
| 02/21/2013 | US20130045275 Sustained-release chitosan capsules comprising chitosan and phytic acid |
| 02/21/2013 | US20130045270 Method of use of stabilized growth factor in skin care |
| 02/21/2013 | US20130045267 Methods of using agents that modulate claudin expression |
| 02/21/2013 | US20130045249 Glycosaminoglycans |
| 02/21/2013 | US20130045244 Modified adam disintegrin domain polypeptides and uses thereof |
| 02/21/2013 | US20130045240 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 02/21/2013 | US20130045239 Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists |
| 02/21/2013 | US20130045236 Diagnostic and therapeutic uses of soluble fc-epsilon receptor i for ige-mediated disorders |
| 02/21/2013 | US20130045216 Method for Treating Amyloid Disease |
| 02/21/2013 | US20130045215 Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
| 02/21/2013 | US20130045214 P53 modulator and cancer target |
| 02/21/2013 | US20130045212 Biological Materials and Uses Thereof |
| 02/21/2013 | US20130045203 Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
| 02/21/2013 | US20130045196 Enzymatic wound debriding compositions with enhanced enzymatic activity |
| 02/21/2013 | US20130045195 Proteases for Degrading Gluten |
| 02/21/2013 | US20130045194 Delivery of Cholesteryl Ester to Steroidogenic Tissues |
| 02/21/2013 | US20130045192 Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| 02/21/2013 | US20130045186 Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby |
| 02/21/2013 | US20130045183 Boswellia oil, its fractions and compositions for enhancing brain function |
| 02/21/2013 | US20130045180 Vaccines, immunotherapeutics and methods for using the same |
| 02/21/2013 | US20130045179 Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
| 02/21/2013 | US20130045171 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 02/21/2013 | US20130045163 Treatment of metastatic tumors |
| 02/21/2013 | US20130045162 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | US20130045160 Magnetic Nano-Composite for Contrast Agent, Intelligent Contrast Agent, Drug Delivery Agent for Simultaneous Diagnosis and Treatment, and Separation Agent for Target Substance |
| 02/21/2013 | DE102011052816A1 Verwendung von Interferon-beta zur Behandlung von Alopecia areata Use of interferon-beta for the treatment of alopecia areata |
| 02/21/2013 | CA2849015A1 Transferrin-tumstatin fusion protein and methods for producing and using the same |
| 02/21/2013 | CA2846230A1 Treatments for gastrointestinal disorders |
| 02/21/2013 | CA2845617A1 Cardiovascular therapeutics |
| 02/21/2013 | CA2845267A1 Low protein percentage gelling compositions |
| 02/21/2013 | CA2844644A1 Plasminogen and plasmin variants |
| 02/21/2013 | CA2842887A1 Mphosph1 peptides and vaccines including the same |
| 02/20/2013 | EP2559759A1 Custom-made meganuclease and use thereof |
| 02/20/2013 | EP2559700A2 Compositions and methods of using proislet peptides and analogs thereof |
| 02/20/2013 | EP2559698A2 Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies |
| 02/20/2013 | EP2559441A2 Protein complex for intracellular delivery and uses thereof |